BioCentury
ARTICLE | Clinical News

Protagonist shares halved on UC failure

March 26, 2018 6:13 PM UTC

Protagonist Therapeutics Inc. (NASDAQ:PTGX) was down $11.68 (57%) to $8.75 on Monday after the company discontinued the Phase IIb PROPEL trial of PTG-100 to treat moderate to severe ulcerative colitis. Protagonist said it will decide whether to start a Phase II/III trial of the candidate to treat chronic pouchitis after a full review of PROPEL's interim data.

With Monday's move, Protagonist shed almost $250 million in market cap...